November 3, 2005

Experimental drug slows tumor growth

CHICAGO (Reuters) - Amgen Inc. and Abgenix Inc. said on
Thursday a late-stage study found its experimental drug
panitumumab helped slow tumor progression in patients with
advanced colon cancer who had failed multiple other therapies.

In the 463-patient trial, patients who received panitumumab
every two weeks showed a 46 percent decrease in tumor
progression rate versus those who received best supportive care
alone, the companies said.

The result was better than the pre-set goal of a 33 percent
decrease in tumor progression, they said.

"We are very encouraged by the results of this pivotal
study and what panitumumab could mean for patients with
advanced colorectal cancer," said Bill Ringo, president and
chief executive officer of Abgenix.

The news sent shares of Amgen and Abgenix sharply higher
while dragging down shares of ImClone Systems Inc., maker of a
rival drug.